Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.